Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Clearmind Medicine Inc. (CMND) is the issuer named in an amended beneficial-ownership report by Iroquois Capital Management, LLC, its president Richard Abbe, and Kimberly Page, who are both directors of Iroquois Master Fund. As of September 30, 2026, the reporting-person cover pages list beneficial ownership of 335,000 common shares for Iroquois Capital Management and Kimberly Page, and 650,000 for Abbe; these amounts include shares issuable upon exercise of warrants. Iroquois Master Fund held no common shares and warrants to purchase 335,000 shares, while ICIG held no common shares and warrants to purchase 315,000 shares. The warrant terms restrict exercise if post-exercise beneficial ownership would exceed 9.99%; certain warrants have a 4.99% blocker. The reported 9.99% ownership percentages are based on 2,145,211 common shares outstanding as of July 31, 2026.
Key Figures
Beneficial ownership — Iroquois Capital Management, LLC:335,000 sharesBeneficial ownership — Richard Abbe:650,000 sharesBeneficial ownership — Kimberly Page:335,000 shares+5 more
8 metrics
Beneficial ownership — Iroquois Capital Management, LLC335,000 sharesAs of September 30, 2026; includes shares issuable upon warrant exercise.
Beneficial ownership — Richard Abbe650,000 sharesAs of September 30, 2026; includes shares issuable upon warrant exercise.
Beneficial ownership — Kimberly Page335,000 sharesAs of September 30, 2026; includes shares issuable upon warrant exercise.
Iroquois Master Fund reported warrants335,000 sharesWarrants to purchase common shares as of September 30, 2026.
ICIG reported warrants315,000 sharesWarrants to purchase common shares as of September 30, 2026.
Common shares outstanding2,145,211 sharesAs of July 31, 2026; used as the basis for reported ownership percentages.
Reported ownership percentage9.99%Reported for each person; gives effect to applicable blockers.
Certain warrant exercise blocker4.99%Certain reported warrants are subject to this blocker.
Key Terms
beneficial ownership, Reported Warrants, Blockers, shared voting power, +1 more
5 terms
beneficial ownershipregulatory
"may be deemed to be the beneficial owner"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Reported Warrantstechnical
"the Company's reported warrants (the "Reported Warrants")"
Blockerstechnical
"(collectively, the "Blockers")"
shared voting powertechnical
"Shared Voting Power 335,000.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powertechnical
"Shared Dispositive Power 335,000.00"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many Clearmind (CMND) warrants did the Iroquois entities report?
Iroquois Master Fund held warrants to purchase 335,000 Clearmind common shares, and ICIG held warrants to purchase 315,000 shares, as of September 30, 2026. Both entities held zero common shares.
Who has investment authority over the Clearmind (CMND) warrants?
Richard Abbe and Kimberly Page share authority and responsibility for investments made for Iroquois Master Fund. Abbe has sole authority and responsibility for investments made for ICIG. Iroquois Capital Management is the investment advisor to Iroquois Master Fund.
What limits apply to exercising Clearmind (CMND) warrants?
The reported warrants cannot be exercised to the extent that exercise would leave the reporting persons beneficially owning more than 9.99% of outstanding common shares. Certain warrants are subject to a 4.99% blocker instead.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 6)
Clearmind Medicine Inc.
(Name of Issuer)
Common Shares, no par value
(Title of Class of Securities)
185053600
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
185053600
1
Names of Reporting Persons
Iroquois Capital Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
335,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
335,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
335,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: Includes 335,000 Common Shares issuable upon exercise of Warrants (See Item 4). As more fully described in Item 4, certain Warrants are subject to a 9.99% blocker (other than certain Warrants which are subject to a 4.99% blocker), and the percentage set forth in row (11) gives effect to such blockers. The shares reported in rows (6), (8) and (9) show the number of Common Shares issuable upon exercise of such reported securities, giving effect to the 9.99% blocker.
SCHEDULE 13G
CUSIP Number(s):
185053600
1
Names of Reporting Persons
Richard Abbe
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
315,000.00
6
Shared Voting Power
335,000.00
7
Sole Dispositive Power
315,000.00
8
Shared Dispositive Power
335,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
650,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: Includes 650,000 Common Shares issuable upon exercise of Warrants (See Item 4). As more fully described in Item 4, certain Warrants are subject to a 9.99% blocker (other than certain Warrants which are subject to a 4.99% blocker), and the percentage set forth in row (11) gives effect to such blockers. The shares reported in rows (5), (6), (7), (8) and (9) show the number of Common Shares issuable upon exercise of such reported securities, without giving effect to the 9.99% blocker.
SCHEDULE 13G
CUSIP Number(s):
185053600
1
Names of Reporting Persons
Kimberly Page
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
335,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
335,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
335,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Includes 335,000 Common Shares issuable upon exercise of Warrants (See Item 4. As more fully described in Item 4, certain Warrants are subject to a 9.99% blocker (other than certain Warrants which are subject to a 4.99% blocker), and the percentage set forth in row (11) gives effect to such blockers. The shares reported in rows (6), (8) and (9) show the number of Common Shares issuable upon exercise of such reported securities, without giving effect to the 9.99% blocker.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Clearmind Medicine Inc.
(b)
Address of issuer's principal executive offices:
101-1220 West 6th Avenue, Vancouver, British Columbia V6H1A5
Item 2.
(a)
Name of person filing:
This statement is being filed by (i) Iroquois Capital Management LLC, a Delaware limited liability company ("Iroquois"), (ii) Richard Abbe, and (iii) Kimberly Page ("Mr. Abbe" and "Ms. Page," together with Iroquois, the "Reporting Persons").
Mr. Abbe shares authority and responsibility for the investments made on behalf of Iroquois Master Fund Ltd. ("Iroquois Master Fund") with Ms. Kimberly Page, each of whom is a director of the Iroquois Master Fund. As such, Mr. Abbe and Ms. Page may each be deemed to be the beneficial owner of all Common Shares held by Iroquois Master Fund. Iroquois Capital is the investment advisor for Iroquois Master Fund and Mr. Abbe is the President of Iroquois Capital. Mr. Abbe has the sole authority and responsibility for the investments made on behalf of Iroquois Capital Investment Group LLC ("ICIG"). As such, Mr. Abbe may be deemed to be the beneficial owner of all Common Shares held by Iroquois Master Fund and ICIG. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of Common Shares owned by another Reporting Person.
(b)
Address or principal business office or, if none, residence:
The principal business address for each of the Reporting Persons is 2 Overhill Road, Scarsdale, NY 10583.
(c)
Citizenship:
Iroquois Capital Management LLC is a Delaware limited liability company. Richard Abbe is an individual who is a citizen of the United States of America. Kimberly Page is an individual who is a citizen of the United States of America.
(d)
Title of class of securities:
Common Shares, no par value
(e)
CUSIP No.:
185053600
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See Item 9 on the cover pages hereto. As of the date of the event which requires filing of this statement, Iroquois Master Fund held 0 Common Shares and Reported Warrants to purchase 335,000 Common Shares, and ICIG held 0 Common Shares and Reported Warrants to purchase 315,000 Common Shares. Pursuant to the terms of the Reported Warrants, the Reporting Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding Common Shares (other than certain Reported Warrants which are subject to a 4.99% blocker) (collectively, the "Blockers").
(b)
Percent of class:
See Item 11 on the cover pages hereto. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 2,145,211 Common Shares outstanding as of July 31, 2026 as represented in the Company's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on September 10, 2026, and assumes the exercise of the Company's reported warrants (the "Reported Warrants"), each subject to the 9.99% Blockers. The percentage set forth in Item 11 of the cover page for each Reporting Person gives effect to the Blockers, if applicable.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Item 5 on the cover pages hereto.
(ii) Shared power to vote or to direct the vote:
See Item 6 on the cover pages hereto.
(iii) Sole power to dispose or to direct the disposition of:
See Item 7 on the cover pages hereto.
(iv) Shared power to dispose or to direct the disposition of:
See Item 8 on the cover pages hereto.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.